Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T19:57:20.917Z.
Calculation as of: 2026-10-06T19:57:20.917Z.
Quote observation: 2026-10-06T19:55:15.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 5f3696a2d024229c19dd1691f2f438020e28c75ff27c8cf4c9d796e14bd4a3b5
PE RATIO
N/A
Market Cap
$28.03M
PE Ratio
N/A
TTM Avg
1135.14
3Y Avg
1135.14
5Y Avg
1135.14
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| iTonic Holdings Ltd. (ITOC) | $26.05M | N/A | N/A | N/A | N/A |
| ABVC BioPharma, Inc. (ABVC)vs › | $25.22M | N/A | 2021.12 | 2021.12 | 2021.12 |
| InspireMD, Inc. (NSPR)vs › | $24.64M | N/A | N/A | N/A | N/A |
| Atossa Therapeutics, Inc. (ATOS)vs › | $24.44M | N/A | N/A | N/A | N/A |
| aTyr Pharma, Inc. (ATYR)vs › | $27.79M | N/A | N/A | N/A | N/A |
| Tevogen Bio Holdings Inc. (TVGN)vs › | $28.03M | N/A | 1135.14 | 1135.14 | 1135.14 |
| Seres Therapeutics, Inc. (MCRB)vs › | $28.03M | N/A | 20.42 | 20.42 | 20.42 |
| Kyntra Bio, Inc. (KYNB)vs › | $23.92M | N/A | 2502.34 | 2502.34 | 2502.34 |
| OneMedNet Corporation (ONMD)vs › | $28.59M | N/A | 414.61 | 414.61 | 195.55 |
| TherapeuticsMD, Inc. (TXMD)vs › | $23.26M | N/A | 89.23 | 89.23 | 89.23 |
Trailing P/E
N/A
Forward P/E
N/A
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
